
Every investment starts with a thesis. What happens after the check clears is where we find out if the thesis was right.
We don't just back founders and wait for the headline moment. We watch what happens in between, the traction that builds quietly before it ever becomes a press release. Here's what that's looked like across a few companies in our portfolio.
When we led Gameball's Pre-Series A out of our Dubai-based MENA Global Investment Hub, the thesis was clear: MENA's e-commerce landscape needed a retention layer built for how the region actually shops, not a retrofitted Western tool.
Gameball has scaled to process over $14B in annualized GMV across 3,000+ businesses, becoming a core retention tool for enterprise brands in the region. That's not a projection. That's where the company stands today, and it's exactly the kind of growth that validates a regional thesis before it validates a specific company.
Healthcare software has never lacked data. What it's lacked is software that does something with it. XelaOS has grown by turning fragmented clinical data into real-time action, connecting systems that used to require clinicians to manually stitch information themselves.
The shift we backed wasn't "better dashboards." It was software that executes, and that's the direction the company has kept building in.
Cross-border investing shouldn't require spreadsheets and disconnected systems. Paisaverse has continued building the infrastructure that lets investors manage portfolios, tax reporting, and compliance across jurisdictions through a single computational layer, growing alongside a genuinely global base of capital.
ode has kept building toward its original bet: that the next wave of social technology helps people spend more time together in the real world, not more time online, starting with college campuses.
Thurgood has continued making employment advocacy more accessible through AI-powered representation. Faro has kept building the trust layer that developers and AI agents rely on before taking action. Different categories, same throughline: each one is executing on the specific problem we backed them to solve, not chasing whatever's trending.
None of these companies grew by accident. They grew because the mechanism in the original pitch proved real: a retention platform that regional merchants actually adopted, a clinical workflow tool that providers actually used, an infrastructure layer that global investors actually needed.
That's the part of the portfolio we watch most closely. Not because the milestones aren't worth celebrating; they are. But because they're proof that the thesis held up once it left the pitch deck.
We'd rather be in the room for that part.